The Use of Transcranial Direct Current Stimulation (TDCS) to Enhance the Rehabilitative Effect of Vision Restoration Therapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Lotfi Merabet, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:
NCT00921427
First received: June 14, 2009
Last updated: March 20, 2012
Last verified: March 2012
  Purpose

The purpose of our study is to explore the efficacy of combination of brain stimulation with visual rehabilitation in patients with visual field loss resulting from brain lesions. It is shown that the effect of sensorimotor training of hand can be enhanced in patients with stroke using brain stimulation. We decided to explore this combination for visual field loss because visual dysfunction following brain lesions is considered intractable. We hypothesize that combination of noninvasive brain stimulation, in the form of transcranial direct current stimulation (tDCS), with visual rehabilitation would have greater efficacy than visual rehabilitation alone.


Condition Intervention Phase
Hemianopia
Quadrantanopia
Scotoma
Visual Field Loss
Behavioral: Vision Restoration Therapy (VRT)
Device: Transcranial direct current stimulation (tDCS)
Phase 0

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Beth Israel Deaconess Medical Center:

Primary Outcome Measures:
  • Visual Field Gain in Degrees [ Time Frame: Once every month for three months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Visual Field test- Percent accuracy of detection [ Time Frame: Once every month for three months ] [ Designated as safety issue: No ]
  • Functional Questionnaire (Impact of Vision Impairment Profile) [ Time Frame: Once every month for three months ] [ Designated as safety issue: No ]
  • Subjective Drawing of the Visual Field (area of blind field in sq. mm) [ Time Frame: Once every month for three months ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: November 2007
Study Completion Date: March 2012
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: VRT and active tDCS
Patients will receive tDCS (noninvasive brain stimulation) concurrently with vision restoration therapy. TDCS is delivered using a small battery-operated device. Electrical leads from the device are connected to saline soaked sponges that are placed at strategic locations on the skull corresponding to areas of the brain that need to be stimulated (in this case, the visual cortex). The dosage will be set to 2 mA/min for 30 minutes, twice a day for 3 days a week for 12 weeks.
Behavioral: Vision Restoration Therapy (VRT)
30 min, twice a day, 3 days a week, 12 weeks
Device: Transcranial direct current stimulation (tDCS)
2 mA/min, 30 min, twice a day, 3 days a week for 12 weeks
Sham Comparator: VRT combined with sham tDCS
Patients will receive sham tDCS concurrently with vision restoration therapy. Electrical leads from the tDCS device will be connected to saline soaked sponges placed at strategic locations on the skull, in a similar maner as in the active tDCS group. Current will be turned on for 30 seconds but will be slowly ramped down and turned off. Treatment will continue for 3 days a week for 12 weeks.
Behavioral: Vision Restoration Therapy (VRT)
30 min, twice a day, 3 days a week, 12 weeks

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hemianopic field loss is defined as (a) visual field defect on the same side of visual space in both eyes as determined by monocular perimetry and (b) established structural damage of the post-charismatic visual system as documented by standard neuroimaging techniques (CT or MRI), medical reports, or a combination of these
  • deep scotoma - defined field loss as confirmed by perimetry
  • cognitive, language and motor function sufficient to understand the experiments and follow instructions
  • informed written consent to participate in the study
  • motivation to participate in the VRT program

Exclusion Criteria:

  • any sensory-motor loss other than visual
  • ongoing use of CNS-active medications for an active neurological disease
  • ongoing use of psychoactive medications, such as stimulants, antidepressants, and anti-psychotic medications for an active psychiatric condition
  • presence of additional potential TDCS risk factors:

    • Damaged skin at the site of stimulation (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, etc.)
    • Presence of an electrically, magnetically or mechanically activated implant (including cardiac pacemaker), an intracerebral vascular clip, or any other electrically sensitive support system.
    • Metal in any part of the body, including metal injury to the eye. (Jewelry must be removed during stimulation.)
    • A history of medication-resistant epilepsy in the family
    • Past history of seizures or unexplained spells of loss of consciousness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00921427

Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Investigators
Principal Investigator: Lotfi B Merabet, OD PhD Beth Israel, Harvard Medical School
Study Director: Alvaro Pascual-Leone, MD PhD Beth Israel, Harvard Medical School, Neurology
  More Information

No publications provided

Responsible Party: Lotfi Merabet, PI, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier: NCT00921427     History of Changes
Other Study ID Numbers: 2007-P-000241
Study First Received: June 14, 2009
Last Updated: March 20, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Beth Israel Deaconess Medical Center:
Hemianopia
Rehabilitation
Transcranial direct current stimulation
Visual field

Additional relevant MeSH terms:
Hemianopsia
Scotoma
Blindness
Eye Diseases
Nervous System Diseases
Neurologic Manifestations
Sensation Disorders
Signs and Symptoms
Vision Disorders

ClinicalTrials.gov processed this record on October 29, 2014